Prime Medicine PRME 深 滬
已收盤 10-16 16:00:00 美东时间
3.47
-0.140
-3.88%
華盛通- 最 高3.605
- 今 開3.55
- 成交量 439.28万股
- 最 低 3.41
- 昨 收 3.61
- 總市值 6.29亿
- 52周最高 5.20
- 市盈率 靜 --
- 換手率 2.42%
- 52周最低 2.67
- 委 比 75.91%
- 總股本 1.81亿
- 歷史最高 21.73
- 量 比 0.85
- 振 幅 5.40%
- 歷史最低 1.11
- 每 手 1
- 風險率 0.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index surging over 250 points on Tuesday. Shares of Apogee Enterprises Inc (NASDAQ:APOG) rose sharply after the company announced better-than-expected second-quarter financial results and raised its FY27 guidance above estimates. Apogee Enterprises reporte...
10-06 21:59
Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday
With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Tamboran Resources Corp. (NYSE:TBN) to post a quarterly loss of 30 cents per share on revenue of $3.82 million before the opening bell, according t...
09-25 15:24
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
09-25 04:02
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine's PM647, an in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD), has received FDA IND clearance, allowing clinical studies to begin in the U.S. PM647 aims to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, addressing both lung and liver manifestations of AATD. The Phase 1/2 trial will evaluate safety, tolerability, and efficacy in adults with AATD, initially targeting lung-only manifestations before expanding to ...
09-24 20:01
Anthropic IPO前亮科研牌：Claude“自主发现”类CRISPR系统，基因编辑板块遭遇“AI替代焦虑”
周三，美股基因编辑公司股价走低。此前，Anthropic宣布，其AI模型Claude“自主发现”了一种类似于基因编辑工具CRISPR的新型酶系统。 个股方面，...
09-24 07:21
Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) said that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR. Notab...
09-24 02:33
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc. announced that its management will participate in three upcoming conferences: the Wells Fargo Healthcare Conference in Boston on September 10, the H.C. Wainwright Global Investment Conference in New York on September 15, and the Morgan Stanley Global Healthcare Conference in New York on September 16. Live audio webcasts of the fireside chats will be available on the company’s website, with replays accessible for 90 days. Prim...
09-03 12:00
Moderna(MRNA.US)mRNA癌症疫苗重大突破引爆市场情绪！生物科技板块估值重估可能才刚开始
生物科技行业在很大程度上受到临床事件的驱动——一项三期临床试验的成功或失败，不仅可以推动直接参与其中的公司股价大幅波动，也可能影响它们所代表的整个治疗技术类别...
08-25 11:45
美股大行评级 | 潜在涨幅1610.53%！Ascendiant Capital上调Alzamend Neuro目标价至26美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Alzamend Neuro"买入"评级，目标价从25美元升至26美元；Tigress Financial：维持Legence"买入"评级，目标价从125美元升至130美元
08-20 08:39
